Abstract | OBJECTIVE: DATA SOURCES: STUDY SELECTION/DATA EXTRACTION: All studies that included humans and contained data describing the use of edoxaban for either stroke prevention in patients with NVAF or the treatment of venous thromboembolism (VTE) were reviewed. DATA SYNTHESIS:
Edoxaban is a target-specific oral anticoagulant, specifically a factor Xa inhibitor. It has been studied in 4 major randomized controlled trials for the prevention of stroke and systemic embolism in patients with NVAF. One randomized controlled trial was conducted for the treatment of VTE. Edoxaban demonstrated noninferiority of the primary efficacy end point compared with warfarin for both approved indications. The most common adverse effect is bleeding, similar to other anticoagulants. A dosing limitation exists related to patients treated for NVAF with creatinine clearance >95 mL/min; these patients experienced decreased efficacy. CONCLUSIONS:
|
Authors | Chelsea Minor, Katie B Tellor, Anastasia L Armbruster |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 49
Issue 7
Pg. 843-50
(Jul 2015)
ISSN: 1542-6270 [Electronic] United States |
PMID | 25855704
(Publication Type: Journal Article, Review)
|
Copyright | © The Author(s) 2015. |
Chemical References |
- Factor Xa Inhibitors
- Pyridines
- Thiazoles
- edoxaban
|
Topics |
- Atrial Fibrillation
(drug therapy)
- Drug Interactions
- Factor Xa Inhibitors
(pharmacology, therapeutic use)
- Hemorrhage
(chemically induced)
- Humans
- Pyridines
(pharmacology, therapeutic use)
- Randomized Controlled Trials as Topic
- Stroke
(prevention & control)
- Thiazoles
(pharmacology, therapeutic use)
- Venous Thromboembolism
(drug therapy)
|